Tags

Type your tag names separated by a space and hit enter

Neuroprotection in Huntington's disease: a 2-year study on minocycline.
Int Clin Psychopharmacol. 2004 Nov; 19(6):337-42.IC

Abstract

Huntington's disease (HD), a relentlessly progressive neurodegenerative disorder, is characterized by a clinical triad of psychiatric, cognitive and motor disturbances. The antibiotic minocycline, a caspase inhibitor exhibiting antiapoptotic properties, has been shown to prolong survival in the transgenic mouse model of HD. We administrated minocycline to 14 patients with genetically confirmed HD. The patients were psychiatrically, neurologically and neuropsychologically evaluated at baseline, and after 6 and 24 months of treatment, using the Unified HD Rating Scale and a neuropsychological test battery. After 12 months, three patients were lost to follow-up so that 11 patients were analysed at the endpoint. Minocycline was well tolerated. Unlike the expected natural course of HD, patients exhibited stabilization in general motor and neuropsychological function at endpoint, after improving in the first 6 months. Moreover, we found a significant amelioration of psychiatric symptoms that was not apparent after the first 6 months. In detail, the Mini-Mental State Examination, the Total Motor Score, the Total Functional Capacity Scale and the Independence Scale, as the most prominent scales in HD, were stabilized after 3 years of treatment. Our results confirm previous animal studies and indicate a neuroprotective effect of this agent in HD. A long-term, double-blind, placebo-controlled trial appears highly warranted for definitively establishing the value of minocycline in HD.

Authors+Show Affiliations

Department of Psychiatry, Graz Medical University, Graz, Austria. raphael.bonelli@klinikum-graz.atNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15486519

Citation

Bonelli, Raphael M., et al. "Neuroprotection in Huntington's Disease: a 2-year Study On Minocycline." International Clinical Psychopharmacology, vol. 19, no. 6, 2004, pp. 337-42.
Bonelli RM, Hödl AK, Hofmann P, et al. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol. 2004;19(6):337-42.
Bonelli, R. M., Hödl, A. K., Hofmann, P., & Kapfhammer, H. P. (2004). Neuroprotection in Huntington's disease: a 2-year study on minocycline. International Clinical Psychopharmacology, 19(6), 337-42.
Bonelli RM, et al. Neuroprotection in Huntington's Disease: a 2-year Study On Minocycline. Int Clin Psychopharmacol. 2004;19(6):337-42. PubMed PMID: 15486519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroprotection in Huntington's disease: a 2-year study on minocycline. AU - Bonelli,Raphael M, AU - Hödl,Anna K, AU - Hofmann,Peter, AU - Kapfhammer,Hans-Peter, PY - 2004/10/16/pubmed PY - 2005/2/16/medline PY - 2004/10/16/entrez SP - 337 EP - 42 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 19 IS - 6 N2 - Huntington's disease (HD), a relentlessly progressive neurodegenerative disorder, is characterized by a clinical triad of psychiatric, cognitive and motor disturbances. The antibiotic minocycline, a caspase inhibitor exhibiting antiapoptotic properties, has been shown to prolong survival in the transgenic mouse model of HD. We administrated minocycline to 14 patients with genetically confirmed HD. The patients were psychiatrically, neurologically and neuropsychologically evaluated at baseline, and after 6 and 24 months of treatment, using the Unified HD Rating Scale and a neuropsychological test battery. After 12 months, three patients were lost to follow-up so that 11 patients were analysed at the endpoint. Minocycline was well tolerated. Unlike the expected natural course of HD, patients exhibited stabilization in general motor and neuropsychological function at endpoint, after improving in the first 6 months. Moreover, we found a significant amelioration of psychiatric symptoms that was not apparent after the first 6 months. In detail, the Mini-Mental State Examination, the Total Motor Score, the Total Functional Capacity Scale and the Independence Scale, as the most prominent scales in HD, were stabilized after 3 years of treatment. Our results confirm previous animal studies and indicate a neuroprotective effect of this agent in HD. A long-term, double-blind, placebo-controlled trial appears highly warranted for definitively establishing the value of minocycline in HD. SN - 0268-1315 UR - https://www.unboundmedicine.com/medline/citation/15486519/Neuroprotection_in_Huntington's_disease:_a_2_year_study_on_minocycline_ L2 - https://doi.org/10.1097/00004850-200411000-00004 DB - PRIME DP - Unbound Medicine ER -